Stock Scorecard
Stock Summary for Cerus Corp (CERS) - $1.66 as of 4/25/2024 9:20:04 AM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CERS
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CERS
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CERS
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for CERS
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for CERS
Financial Details for CERS
Company Overview |
|
---|---|
Ticker | CERS |
Company Name | Cerus Corp |
Country | USA |
Description | Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California. |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 1.66 |
Last Day Price Updated | 4/25/2024 9:20:04 AM EST |
Last Day Volume | 590,027 |
Average Daily Volume | 1,890,241 |
52-Week High | 3.08 |
52-Week Low | 1.21 |
Last Price to 52 Week Low | 37.19% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 47.46 |
Sector PE | 60.54 |
5-Year Average PE | -13.43 |
Free Cash Flow Ratio | 4.61 |
Industry Free Cash Flow Ratio | 61.03 |
Sector Free Cash Flow Ratio | 30.19 |
Current Ratio Most Recent Quarter | 2.14 |
Total Cash Per Share | 0.36 |
Book Value Per Share Most Recent Quarter | 0.29 |
Price to Book Ratio | 6.51 |
Industry Price to Book Ratio | 5.21 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 2.19 |
Industry Price to Sales Ratio Twelve Trailing Months | 14.23 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 181,283,000 |
Market Capitalization | 300,929,780 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 12.37% |
Reported EPS 12 Trailing Months | -0.21 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -0.19 |
Net Income Twelve Trailing Months | -37,489,000 |
Net Income Past Year | -37,489,000 |
Net Income Prior Year | -42,779,000 |
Quarterly Revenue Growth YOY | 6.20% |
5-Year Revenue Growth | 19.83% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 65,852,000 |
Total Cash Past Year | 65,852,000 |
Total Cash Prior Year | 102,154,000 |
Net Cash Position Most Recent Quarter | -93,740,000 |
Net Cash Position Past Year | -93,740,000 |
Long Term Debt Past Year | 159,592,000 |
Long Term Debt Prior Year | 69,803,000 |
Total Debt Most Recent Quarter | 159,592,000 |
Equity to Debt Ratio Past Year | 0.25 |
Equity to Debt Ratio Most Recent Quarter | 0.25 |
Total Stockholder Equity Past Year | 52,650,000 |
Total Stockholder Equity Prior Year | 67,610,000 |
Total Stockholder Equity Most Recent Quarter | 52,650,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.09 |
MACD Signal | -0.09 |
20-Day Bollinger Lower Band | 1.54 |
20-Day Bollinger Middle Band | 1.99 |
20-Day Bollinger Upper Band | 2.44 |
Beta | 1.30 |
RSI | 40.86 |
50-Day SMA | 1.95 |
200-Day SMA | 4.56 |
System |
|
Modified | 4/8/2024 8:35:36 PM EST |